[go: up one dir, main page]

EE05263B1 - IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks - Google Patents

IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks

Info

Publication number
EE05263B1
EE05263B1 EEP200300582A EEP200300582A EE05263B1 EE 05263 B1 EE05263 B1 EE 05263B1 EE P200300582 A EEP200300582 A EE P200300582A EE P200300582 A EEP200300582 A EE P200300582A EE 05263 B1 EE05263 B1 EE 05263B1
Authority
EE
Estonia
Prior art keywords
focuses
inhibitors
prevention
treatment
systemic damage
Prior art date
Application number
EEP200300582A
Other languages
English (en)
Estonian (et)
Inventor
Shohami Esther
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of EE200300582A publication Critical patent/EE200300582A/xx
Publication of EE05263B1 publication Critical patent/EE05263B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200300582A 2001-05-25 2002-05-23 IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks EE05263B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112067 2001-05-25
PCT/EP2002/005666 WO2002096456A1 (en) 2001-05-25 2002-05-23 Use of il-18 inhibitors for treating or preventing cns injuries

Publications (2)

Publication Number Publication Date
EE200300582A EE200300582A (et) 2004-02-16
EE05263B1 true EE05263B1 (et) 2010-02-15

Family

ID=8177454

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300582A EE05263B1 (et) 2001-05-25 2002-05-23 IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks

Country Status (29)

Country Link
US (1) US7655616B2 (lt)
EP (1) EP1390070B1 (lt)
JP (1) JP4344142B2 (lt)
KR (1) KR20040030625A (lt)
CN (1) CN1305529C (lt)
AU (1) AU2002314103B2 (lt)
BG (1) BG66395B1 (lt)
BR (1) BR0210007A (lt)
CA (1) CA2445664C (lt)
CY (1) CY1119190T1 (lt)
CZ (1) CZ307321B6 (lt)
DK (1) DK1390070T3 (lt)
EA (1) EA006744B1 (lt)
EE (1) EE05263B1 (lt)
ES (1) ES2617084T3 (lt)
HR (1) HRP20030842B1 (lt)
HU (1) HU230294B1 (lt)
IL (2) IL159014A0 (lt)
LT (1) LT1390070T (lt)
ME (1) ME00550B (lt)
MX (1) MXPA03010743A (lt)
NO (1) NO331882B1 (lt)
PL (1) PL216228B1 (lt)
PT (1) PT1390070T (lt)
RS (1) RS56006B1 (lt)
SK (1) SK288413B6 (lt)
UA (1) UA80396C2 (lt)
WO (1) WO2002096456A1 (lt)
ZA (1) ZA200308172B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
AU2005258569B2 (en) * 2004-06-30 2012-05-03 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
SI1888100T1 (sl) * 2005-06-03 2012-01-31 Merck Serono Sa Uporaba izooblik il-18pb za zdravljenje in/ali prepreäśevanje nevroloĺ kih vnetnih bolezni
ATE529433T1 (de) 2005-06-10 2011-11-15 Ares Trading Sa Verfahren zur reinigung eines il-18-bindenden proteins
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
PH12016500425B1 (en) * 2013-09-05 2022-07-29 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
JP7274259B2 (ja) * 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873453A (ja) * 1994-09-02 1996-03-19 Otsuka Pharmaceut Co Ltd サイトカイン阻害剤
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE69925581T2 (de) * 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100798545B1 (ko) * 2000-05-05 2008-01-28 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 죽상경화증의 치료 또는 예방을 위한 ｉｌ-18 저해물질의용도
AU2001266289A1 (en) * 2000-06-23 2002-01-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6671553B1 (en) * 2001-05-23 2003-12-30 Pacesetter, Inc. Implantable cardiac lead having terminating connector strain relief and method of manufacture

Also Published As

Publication number Publication date
ME00550B (me) 2011-10-10
IL159014A0 (en) 2004-05-12
SK16032003A3 (sk) 2004-05-04
EE200300582A (et) 2004-02-16
ES2617084T3 (es) 2017-06-15
JP4344142B2 (ja) 2009-10-14
CY1119190T1 (el) 2018-02-14
HU230294B1 (hu) 2015-12-28
SK288413B6 (sk) 2016-10-03
HK1069762A1 (en) 2005-06-03
KR20040030625A (ko) 2004-04-09
PL216228B1 (pl) 2014-03-31
NO20035160L (no) 2003-11-20
US20040191247A1 (en) 2004-09-30
US7655616B2 (en) 2010-02-02
EA006744B1 (ru) 2006-04-28
UA80396C2 (en) 2007-09-25
HUP0304067A3 (en) 2006-01-30
HUP0304067A2 (hu) 2004-03-29
RS56006B1 (sr) 2017-09-29
CZ307321B6 (cs) 2018-06-06
IL159014A (en) 2012-05-31
EA200301299A1 (ru) 2004-04-29
WO2002096456A1 (en) 2002-12-05
ZA200308172B (en) 2004-10-21
BR0210007A (pt) 2004-08-10
PL367545A1 (en) 2005-02-21
CA2445664C (en) 2012-03-06
BG66395B1 (bg) 2013-12-31
CZ20033268A3 (en) 2004-07-14
JP2004534777A (ja) 2004-11-18
CN1535160A (zh) 2004-10-06
NO331882B1 (no) 2012-04-23
HRP20030842B1 (hr) 2017-06-02
CN1305529C (zh) 2007-03-21
AU2002314103B2 (en) 2007-07-12
HRP20030842A2 (en) 2005-08-31
DK1390070T3 (en) 2017-04-24
CA2445664A1 (en) 2002-12-05
MXPA03010743A (es) 2004-03-02
NO20035160D0 (no) 2003-11-20
PT1390070T (pt) 2017-03-01
EP1390070A1 (en) 2004-02-25
BG108451A (en) 2005-02-28
YU89403A (sh) 2006-05-25
EP1390070B1 (en) 2017-02-08
LT1390070T (lt) 2017-03-10
AU2002314103B8 (en) 2002-12-09

Similar Documents

Publication Publication Date Title
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
EE200300449A (et) Metalloproteinaasi inhibiitorid
EE200300439A (et) Metalloproteinaasi inhibiitorid
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DE60234125D1 (de) E inhibitoren
PT1370553E (pt) Inibidores de rhoquinase
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
DE60218138D1 (de) Rho-kinase inhibitoren
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
IS7138A (is) Alkýn-arýl fosfódíesterasa-4 hindrar
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
EE200300450A (et) Metalloproteinaasi inhibiitorid
NO20025307L (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DE60220060D1 (de) Wirbelbildung inhibitor mit opferkörper
FI20011370A0 (fi) Biotunnistusmenetelmä ja sitä hyödyntävä laite
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
SE0301854L (sv) Antiigensättningsbehandling
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
NO20040370L (no) Anvendelse av IL-18-inhibitorer i hypersensitivitetslidelser.
EP1364653A4 (en) CASOASE-3 INHIBITORS
NO20034785L (no) Farmas degree ytiske kombinasjoner basert på pyridoindolonderivater og anticancer-midler
DE60205008D1 (de) Kettelverfahren und -vorrichtung
NO20033160D0 (no) Anordning for behandling av gravann
GB0119460D0 (en) The use of inhibitors of the renin-angiotensin system

Legal Events

Date Code Title Description
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name